3-(ethyl-(3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1,3-thiazol-2-yl)amino)-6-methoxyquinazolin-7-yl)oxy)propyl)amino)propyl dihydrogen phosphate | 723279-47-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(ethyl-(3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1,3-thiazol-2-yl)amino)-6-methoxyquinazolin-7-yl)oxy)propyl)amino)propyl dihydrogen phosphate
• 英文别名: 3-[Ethyl-[3-[4-[[5-[2-(3-fluoroanilino)-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxypropyl]amino]propyl dihydrogen phosphate
• CAS: 723279-47-8
• 化学式: C₂₈H₃₄FN₆O₇PS
• 分子量: 648.652
• InChiKey: MRMMPCTVLCLTQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  44
• 可旋转键数：
  17
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  197
• 氢给体数：
  4
• 氢受体数：
  14

文献信息

• [EN] QUINAZOLINE COMPOUNDS<br/>[FR] COMPOSES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2004058752A1

  公开（公告）日：2004-07-15

  Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a sulphur atom and optionally containing one or more nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  式(I)中的喹唑啉衍生物，其中A是含有硫原子并且可选地含有一个或多个氮原子的5-成员杂芳基；含有它们的组合物，其制备方法以及它们在治疗中的用途。
• Quinazoline compounds
  申请人：Mortlock Austen Andrew

  公开号：US20060058523A1

  公开（公告）日：2006-03-16

  Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a sulphur atom and optionally containing one or more nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  公式（I）中的喹嗪啉衍生物，其中A是含有硫原子并可选地含有一个或多个氮原子的五元杂环芳基；包含它们的组合物，制备它们的过程以及它们在治疗中的使用。
• QUINAZOLINE COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1575946A1

  公开（公告）日：2005-09-21
• COMBINATION THERAPY FOR DISEASES INVOLVING ANGIOGENESIS
  申请人：Bausch & Lomb Incorporated

  公开号：EP2012878A2

  公开（公告）日：2009-01-14
• Combination Therapy for Diseases Involving Angiogenesis
  申请人：Ward Keith W.

  公开号：US20070258976A1

  公开（公告）日：2007-11-08

  A composition useful for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis comprises at least two therapeutic agents selected from the group consisting of compounds that interact with and inhibit a downstream activity of extracellular VEGF, compounds that interact with at least a VEGF receptor and render it substantially unavailable for interacting with VEGF, and compounds that reduce a level of expression of VEGF. The invention also includes a method for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis using such a composition.